globenewswire

Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:15
FLEMINGTON, N.J.--Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has expanded its management team with the appointments of Joseph Bisaha, PhD as Vice President, Clinical Operations and Project Management and David M. Jackson, PhD as Vice President, Diagnostics.
Read more...
 
Anavex Agreement With The Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:13
NEW YORK--Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer's disease.
Read more...
 
American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU) Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:05
SAN RAFAEL, Calif.--BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that new practice guidelines issued by the American College of Medical Genetics and Genomics (ACMG) support the need for lifelong management of PHE levels in patients with phenylketonuria or PKU.
Read more...
 
Vision-Sciences' EndoSheath(R) Technology Offers Patented Solution to "Nightmare Bacteria" Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
ORANGEBURG, N.Y.--An outbreak of "Nightmare Bacteria," also known as the "Super Bug," has raised new alarm bells in the healthcare industry over patient safety.
Read more...
 
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
SOUTH SAN FRANCISCO, Calif.--Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa* (PRT4445), with the oral Factor Xa inhibitor Eliquis® (apixaban).
Read more...
 
Novavax Announces Management Promotions to Support Expanded Clinical Activity in 2014 Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
ROCKVILLE, Md.--Novavax, Inc. (Nasdaq:NVAX) announced a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015.
Read more...
 
Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD) Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
LEIDEN, Netherlands and LONDON--Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to drisapersen and
will retain rights to all other programs for the treatment of Duchenne Muscular Dystrophy (DMD).
Read more...
 
StemCells, Inc. Technology is Featured in Canadian TV Broadcast Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
NEWARK, Calif.--StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and

Error. Page cannot be displayed. Please contact your service provider for more details. (25)

11 PM on the CTV National News.
Read more...
 
Hemispherx Biopharma to Present on January 15 at the Biotech Showcase Held in Conjunction With the 32nd JP Morgan Healthcare Conference in San Francisco Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
PHILADELPHIA--Hemispherx Biopharma (NYSE MKT:HEB), today announced it will make a presentation at the Biotech Showcase held in conjunction with the 32nd JP Morgan Healthcare Conference in San Francisco, California.
Read more...
 
Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
TEL AVIV, Israel--Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Sustained-Release Metadoxine), to treat cognitive dysfunction, announced today that it has appointed David C. Baker as Chief Commercial Officer.
Read more...
 
Vitacost Ranks #2 in Customer Satisfaction Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
BOCA RATON, Fla.--Vitacost.com, Inc. (Nasdaq:VITC), a leading online retailer of health and wellness products, announced today that it has been ranked #2 in customer satisfaction among Internet Retailer's top 100 U.S. websites during the 2013 holiday season, surpassed only by Amazon.com, according to the ForeSee Experience Index (FXI): 2013 U.S. Retail Edition.
Read more...
 
ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2013 Revenue Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
PLEASANTON, Calif.--ZELTIQ®, (Nasdaq:ZLTQ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today preliminary unaudited revenue for the fourth quarter and full year 2013.
Read more...
 
Merrimack to Present Preclinical Data at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
CAMBRIDGE, Mass.--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that preclinical data on an analysis of HER2, HER3 and heregulin levels in gastric and gastroesophageal junction (GEJ) tumors will be presented at the American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium (ASCO GI), January 16-18, 2014 at the Moscone West Building in San Francisco.
Read more...
 
BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
SAN RAFAEL, Calif.--BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the treatment of hemophilia A and has initiated IND-enabling studies.
Read more...
 
Novavax Announces Continuation of RSV Vaccine Partnership With PATH Print E-mail
By GLOBE NEWSWIRE   
Monday, 13 January 2014 02:00
ROCKVILLE, Md.--Novavax, Inc. (Nasdaq:NVAX) announced the continuation of their partnership with PATH to develop Novavax' RSV (respiratory syncytial virus) vaccine for maternal immunization.
Read more...
 
<< Start < Prev 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 Next > End >>

Page 1454 of 1468

Newsletter

BMR:1